<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03499223</url>
  </required_header>
  <id_info>
    <org_study_id>THR-317-002</org_study_id>
    <secondary_id>2017-003897-15</secondary_id>
    <nct_id>NCT03499223</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)</brief_title>
  <official_title>A Phase 2, Randomised, Single-masked, Active-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Intravitreal THR-317 Administered in Combination With Ranibizumab, for the Treatment of Diabetic Macular Oedema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ThromboGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ThromboGenics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the safety of intravitreal THR-317 administered in
      combination with ranibizumab, and to assess the efficacy of the combination treatment in
      improving best-corrected visual acuity (BCVA) and reducing central subfield thickness (CST),
      in subjects with central-involved diabetic macular oedema (CI-DME).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in BCVA</measure>
    <time_frame>At Day 84 (Month 3)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of systemic and ocular adverse events including serious adverse events</measure>
    <time_frame>From Day 0 to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BCVA, by study visit</measure>
    <time_frame>From Day 0 to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CST, based on spectral domain optical coherence tomography (SD-OCT), as assessed by the central reading centre, by study visit</measure>
    <time_frame>From Screening to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal from repeat study treatment and reason for withdrawal</measure>
    <time_frame>At Day 28 and at Day 56</time_frame>
    <description>Number of subjects meeting withdrawal criteria from repeat study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ranibizumab + THR-317</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive intravitreal ranibizumab in combination with THR-317</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham + ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a sham injection in combination with intravitreal ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5mg</intervention_name>
    <description>3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart</description>
    <arm_group_label>Ranibizumab + THR-317</arm_group_label>
    <arm_group_label>Sham + ranibizumab</arm_group_label>
    <other_name>Lucentis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THR-317 8mg</intervention_name>
    <description>3 intravitreal injections of THR-317 8mg, approximately 1 month apart</description>
    <arm_group_label>Ranibizumab + THR-317</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>3 sham injections, approximately 1 month apart. No actual injections. No medication is used.</description>
    <arm_group_label>Sham + ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 years or older

          -  Type 1 or type 2 Diabetes Mellitus

          -  CI-DME with central subfield thickness of ≥ 320μm on Spectralis® SD-OCT or ≥ 305μm on
             non Spectralis SD-OCT, in the study eye

          -  Anti-vascular endothelial growth factor (anti-VEGF) treatment naïve study eye, or poor
             or no response to prior treatment with ranibizumab in the study eye

          -  Reduced vision primarily due to DME, with BCVA ≤ 72 and ≥ 23 ETDRS letter score (≤
             20/40 and ≥ 20/320 Snellen equivalent) in the study eye

          -  Non-proliferative diabetic retinopathy of any stage in the study eye

          -  Written informed consent obtained from the subject prior to screening procedures

        Exclusion Criteria:

          -  Concurrent disease in the study eye, other than CI-DME, that could compromise BCVA,
             require medical or surgical intervention during the study period or could confound
             interpretation of the results

          -  Previous confounding treatments / procedures, or their planned / expected use during
             the study period for up to 30 days after the last administration of study treatment

          -  Any active ocular / intraocular infection or inflammation in either eye

          -  Aphakic study eye

          -  Poorly controlled Diabetes Mellitus

          -  Uncontrolled hypertension

          -  Pregnant or lactating female, or female of child-bearing potential not utilising an
             adequate form of contraception, or male of reproductive potential not utilising
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Global Clinical Development</last_name>
    <phone>+32 (0)16 751 310</phone>
    <email>info@thrombogenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univerzitná nemocnica Bratislava, Nemocnica Ružinov</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univerzitná nemocnica Bratislava, Nemocnica Sv. Cyrila a Metoda</name>
      <address>
        <city>Bratislava</city>
        <zip>851 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultná nemocnica Trenčín</name>
      <address>
        <city>Trenčín</city>
        <zip>911 71</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultná nemocnica s polikliniku Žilina</name>
      <address>
        <city>Žilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oftalvist IMED Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46100</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

